Alcobra Leads Biotech Movers Early Friday

Alcobra Leads Biotech Movers Early Friday


Alcobra saw shares plummet 52% ahead of the market open on Tuesday after its ADHD drug missed a phase three endpoint in clinical trials. Alcobra's shares hit $1.52 apiece in premarket trading Tuesday on the news.



from Biotech News